How Purple Biotech’s CAPTN-3 platform achieved a tri-specific antibody manufacturing milestone with IM1240

Purple Biotech Ltd. (NASDAQ: PPBT) announced a major inflection point in its oncology pipeline with the successful establishment of a commercially viable manufacturing process for IM1240, a tri-specific antibody engineered using its CAPTN-3 platform. The milestone signals that the Israel-based biopharmaceutical company has overcome one of the most difficult hurdles in developing multispecific biologics—scalability—paving the way for a planned Investigational New Drug (IND) filing in 2026 and potential first-in-human studies shortly thereafter.

The announcement ignited a surge in investor confidence, sending Purple Biotech’s stock up nearly 90% during intraday trading as the market interpreted the development as evidence of strong execution. With IM1240 now confirmed to achieve high yield and purity at scale, Purple Biotech positions itself among a small cohort of emerging immuno-oncology firms capable of translating complex tri-specific formats into manufacturable products—a feat that historically separates platform promises from clinical reality.

How the CAPTN-3 platform overcomes one of biotech’s hardest problems: scaling tri-specific antibodies with purity and yield

Tri-specific antibodies are notoriously challenging to produce. Unlike conventional monoclonal or even bispecific antibodies, these molecules contain three functional binding arms—typically combining tumor targeting with immune-cell engagement. Manufacturing such constructs often leads to folding errors, mispairing, and suboptimal yields. Purple Biotech’s CAPTN-3 platform addresses these issues through a “protease-cleavable albumin-bound cap” architecture designed to remain inert in systemic circulation until activated in the tumor microenvironment.

According to the company, the process optimization achieved for IM1240 enables commercially viable yields without compromising structural integrity or pharmacologic function. The cleavable cap design allows the CD3-binding region—which engages T cells—to stay masked until proteases in the tumor microenvironment trigger activation. By restricting full T-cell engagement to the tumor site, CAPTN-3 aims to mitigate systemic cytokine release syndrome (CRS), a toxicity that has limited broader use of T-cell engagers.

The platform’s modularity also allows integration of NKG2A-binding domains, which recruit natural killer (NK) cells and CD8+ T cells to boost anti-tumor response. This dual immune-arm engagement—NK plus T—marks a next-generation approach in multispecific design, expanding efficacy beyond T-cell-only targeting seen in first-wave bispecific antibodies.

For Purple Biotech, the manufacturing milestone validates not only the biology but the chemistry, manufacturing, and controls (CMC) discipline required for clinical scalability. Many competitors have reached proof-of-concept at the bench but stalled before IND-enabling studies due to inability to replicate purity and yield at production volumes. CAPTN-3’s reproducibility changes that dynamic, giving Purple Biotech a tangible head start in a competitive immunotherapy field.

Why investors see the IM1240 milestone as an early de-risking event for Purple Biotech’s pipeline execution trajectory

In capital-markets terms, Purple Biotech’s news represents a de-risking catalyst—a technical validation that reduces uncertainty surrounding the company’s ability to commercialize its science. Analysts covering emerging oncology biotechs often classify milestones as either “scientific” or “executional.” Manufacturing breakthroughs fall into the latter, showing that the company can deliver on process engineering, a prerequisite for regulatory filings and partnership readiness.

Following the announcement, PPBT shares climbed above $1.35 from under $0.60, reflecting renewed investor enthusiasm. The trading volume spiked over 300 million shares—nearly 100 times average daily activity—indicating speculative momentum and institutional attention. Financial portals like TipRanks and Investing.com attributed the price action to the manufacturing update, describing it as “a tangible proof point that CAPTN-3 can scale.”

While Purple Biotech did not release exact yield figures or titer data, its description of “commercially viable” purity implies performance above the threshold needed for clinical-grade GMP production. If validated through upcoming quality control batches, this reduces one of the major risks associated with advancing tri-specific biologics: scalability.

Market watchers also view the milestone as an enabler for non-dilutive financing. Biotechs demonstrating manufacturing competence often attract development partnerships or technology-licensing agreements, improving leverage before further capital raises. That dynamic may play out in 2026, especially if the IND submission remains on schedule and early partnering discussions materialize.

What makes CAPTN-3 and IM1240 distinctive within the crowded multispecific antibody landscape

The CAPTN-3 platform’s hallmark innovation lies in its tumor-activated safety design. By combining tumor antigen 5T4 targeting with CD3 and NKG2A engagement, IM1240 represents a tri-functional molecule that integrates tumor recognition, T-cell activation, and NK-cell stimulation within one construct. This multifaceted approach is designed to counter tumor immune evasion—a major limitation of monotherapy checkpoint inhibitors and earlier bispecifics.

The 5T4 antigen, widely expressed in solid tumors such as renal, colorectal, and pancreatic cancers, provides a broadly addressable entry point. Meanwhile, NKG2A inhibition releases NK and cytotoxic T cells from inhibitory signaling, potentially amplifying cytolytic activity within the tumor microenvironment. The result, if confirmed in future trials, could be improved tumor eradication in otherwise immunologically “cold” tumor types.

Purple Biotech’s decision to prioritize IM1240 as the lead CAPTN-3 asset demonstrates confidence in both its bioengineering platform and its CMC scalability. The milestone effectively establishes CAPTN-3 as more than a research tool—it now appears ready for translational deployment. Given the manufacturing bottlenecks that historically slowed multispecifics like tri-body or tetra-body constructs, this readiness could serve as a differentiator when Purple Biotech seeks clinical or commercial partners.

Industry analysts have drawn comparisons between CAPTN-3 and platforms such as Genmab’s DuoBody, MacroGenics’ DART, and Amgen’s BiTE, all of which advanced bispecific formats. However, tri-specific formats present higher structural complexity, and only a handful of firms have demonstrated stable, manufacturable candidates. Purple Biotech’s achievement therefore positions it within a select tier of innovators expanding multispecific immunotherapy beyond dual targeting.

How this milestone could shape future valuation, partnerships, and biotech sector sentiment in 2025–2026

The significance of this event extends beyond Purple Biotech’s immediate pipeline. In the current biotech climate—where funding is cautious and capital efficiency dominates—tangible manufacturing progress carries substantial signaling power. A successful tri-specific scaling process implies technical maturity and operational credibility, qualities that attract both licensing interest and investor confidence.

For Purple Biotech, the timing is strategic. The company’s preclinical portfolio had faced skepticism over execution risk; achieving CMC readiness rebalances that narrative. With clinical trials still roughly a year away, Purple Biotech gains valuable time to leverage its manufacturing capability into strategic alliances or co-development deals, potentially reducing cash-burn pressure.

Sentiment analysis of online investor discussions and social-media data surrounding #PPBT suggests a sharp pivot toward optimism following the news. Mentions emphasizing “manufacturing success,” “scalable CAPTN-3,” and “tri-specific next-gen” increased by over 400% on retail platforms. Yet, experienced biotech investors remain cautious: without clinical data, valuation expansion may be temporary.

Historically, platform-validation events like this often precede financing rounds. Analysts speculate that Purple Biotech could use the market momentum to raise additional capital on improved terms, though no such plan has been announced. If it secures a partnership or co-development deal ahead of IND submission, that could further stabilize its financial runway through 2027.

From a broader sector perspective, this milestone underscores a growing investor appetite for multispecific antibody platforms capable of demonstrating tangible CMC progress before entering human studies. The market’s enthusiastic response to Purple Biotech mirrors similar reactions seen when smaller immuno-oncology firms de-risked their manufacturing or delivery platforms ahead of pivotal trials.

What industry analysts and scientific observers will monitor next as Purple Biotech transitions toward clinical readiness

Over the next 18 months, attention will turn to the following milestones: first, Good Manufacturing Practice (GMP) batch release and process validation data; second, IND-enabling toxicology studies confirming safety and pharmacokinetic behavior; and third, FDA acceptance of the IND in 2026. Each of these steps represents a value-inflection point for both investors and potential partners.

Regulatory agencies typically scrutinize tri-specific antibody submissions more rigorously due to their complexity and immunogenic risk. Purple Biotech’s ability to demonstrate consistent lot-to-lot purity and stability under GMP conditions will be essential. If the CAPTN-3 platform performs as expected, it could pave the way for multiple follow-on programs using the same modular backbone—multiplying its commercial potential.

Beyond IM1240, analysts anticipate that Purple Biotech may unveil additional CAPTN-3 candidates targeting other tumor antigens or immune-modulatory receptors. Should manufacturing reproducibility hold, the company could effectively franchise the platform across multiple oncology indications, enhancing long-term valuation.

For investors, the near-term challenge lies in balancing enthusiasm with realism. The share price rally signals speculative optimism, but the absence of clinical data means volatility will persist. Still, as a case study in how manufacturing execution can materially shift perception, Purple Biotech’s IM1240 milestone reinforces that biotech success today often begins in the process suite, not the clinic.